ReviewBiomolecules & therapeutics2014
Genetically engineered mouse models for drug development and preclinical trials.
Review in Biomolecules & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- ABE9 fused to SpRY Cas9 nickase enables precise generation of bystander free mouse models.Scientific reports · 2026Article
- A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response.Science translational medicine · 2025Article
- Article
- A review of animal models utilized in preclinical studies of approved gene therapy products: trends and insights.Laboratory animal research · 2024Review
- High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models.Nature communications · 2024Article
- Advances in the Application of Preclinical Models in Photodynamic Therapy for Tumor: A Narrative Review.Pharmaceutics · 2023Review
- Rosa26-LSL-dCas9-VPR: a versatile mouse model for tissue specific and simultaneous activation of multiple genes for drug discovery.Scientific reports · 2022Article
- New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies.Life (Basel, Switzerland) · 2021Review
- A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders.Frontiers in endocrinology · 2021Review
- Reproducible differentiation and characterization of neurons from mouse embryonic stem cells.MethodsX · 2020Article
- Article
- A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions.Cancers · 2019Article
- Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux.Journal of cancer research and clinical oncology · 2019Review
- Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX).PeerJ · 2019Article
- Transgenic Mouse Models in Cancer Research.Frontiers in oncology · 2018Review
- The Use of Omic Technologies Applied to Traditional Chinese Medicine Research.Evidence-based complementary and alternative medicine : eCAM · 2017Review
- The Arteriovenous (AV) Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering.Journal of visualized experiments : JoVE · 2016Article
- Animal models for photodynamic therapy (PDT).Bioscience reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug development and preclinical trials are challenging processes and more than 80% to 90% of drug candidates fail to gain approval from the United States Food and Drug Administration. Predictive and efficient tools are required to discover high quality targets and increase the probability of success in the process of new drug development. One such solution to the challenges faced in the development of new drugs and combination therapies is the use of low-cost and experimentally manageable in vivo animal models. Since the 1980's, scientists have been able to genetically modify the mouse genome by removing or replacing a specific gene, which has improved the identification and validation of target genes of interest. Now genetically engineered mouse models (GEMMs) are widely used and have proved to be a powerful tool in drug discovery processes. This review particularly covers recent fascinating technologies for drug discovery and preclinical trials, targeted transgenesis and RNAi mouse, including application and combination of inducible system. Improvements in technologies and the development of new GEMMs are expected to guide future applications of these models to drug discovery and preclinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.